São Paulo, November 28, 2025 – Eurofarma, the first pharmaceutical multinational with 100% Brazilian capital and a reference among the best in the sector, has just been elected the best pharmaceutical company in ESG in the 2025 Época Negócios Yearbook, reinforcing its historical commitment to responsible, sustainable practices aligned with social development.

In addition to its leadership in ESG, Eurofarma also shows continuous evolution in the categories of financial performance and innovation, areas in which the company has consistently invested over the last few years. The company also maintained a prominent position in future vision, an attribute that highlights its ability to invest in technology and lead initiatives that ensure sustainable long-term growth.

The set of these results reaffirms Eurofarma's strategy of balancing operational excellence, corporate responsibility, and investment in innovation, contributing to the advancement of the pharmaceutical industry and the generation of value for society as a whole. This recognition consolidates the company as a reference in environmental, social, and governance issues, reflecting a consistent, transparent performance guided by a future vision that places sustainability at the heart of strategic decisions.

About Eurofarma
Founded in 1972, Eurofarma operates in the health sector with the production and marketing of products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as medical prescription, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing production services to third parties. With broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving the main medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13.3 thousand employees and 11 factories, with a total production of 600 million units in 2024. In the same year, it invested more than R$ 800 million in innovation projects and achieved total net revenue of R$ 11 billion.

Eurofarma on social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | Youtube: @eurofarmalab

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - +55 11 97644-4496 
Guilherme Gaspar - +55 11 98285-6000